PCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France
|
|
|
- Wesley Sharp
- 5 years ago
- Views:
Transcription
1 PCI for Left Main Coronary Artery Stenosis Jean Fajadet Clinique Pasteur, Toulouse, France Athens, October 19, 2018
2 Left Main Coronary Artery Disease Significant unprotected left main coronary artery disease occurs in 5-7% of patients undergoing coronary angiography. The LMS supplies 84% of the blood flow to the LV in a right dominant system (with 16% supplied by the RCA) and 100% of the blood flow to the LV in a left dominant system.
3 Left Main Coronary Artery Disease Distribution of the atherosclerotic plaque Plaque is located in the lateral wall (area of low shear stress) while sparing the flow divider region (high shear)
4 Distribution of plaque in the distal LMCA
5 Left Main Coronary Artery Disease Distal location >70% of cases Calcified >50% of cases MVD >70% of cases
6 Yusuf et al. Lancet 1994; 344:563
7 Lancet 1978;1:263
8
9 Revascularisation for Left Main Lesion Basics for decision-making Knowledge Data from RCT s, registries, meta-analysis Guidelines Experience Results from local heart team Clinical Judgment Evolution of Technology & Techniques Global appraisal of the Patient
10 Revascularisation for Left Main Lesion Basics for decision-making Knowledge Data from RCT s, registries, meta-analysis Guidelines Experience Results from local heart team Clinical Judgment Evolution of Technology & Techniques Global appraisal of the Patient
11 Vessel Distribution in LM Population According to Syntax Score Terciles 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% LM + 3VD LM + 2VD LM + 1VD LM isolated Low Syntax Intermediate Syn tax High Syntax 4% 35% 61% 29% 11% 59% 7% 27% 66% Nondistal Distal Both
12 SYNTAX Left Main MACCE at 5-year follow-up CABG = 31.0%, PCI = 36.9%, p = 0.12 Mohr et al. Lancet 2013; 381:
13 Randomized Trial of Stents Versus Bypass Surgery for Left Main Coronary Artery Disease 5-Year Outcomes of the PRECOMBAT Study Death of any cause, MI, or stroke MACCE Ahn et al. J Am Coll Cardiol 2015;65:
14 Outcomes AfterPCI or CABG in Patients With Unprotected Left Main Disease Meta analysis of SYNTAX & PRECOMBAT PCI (%) CABG (%) p value MACCE Death Cardiac death MI Stroke Death, MI, stroke All revascularisation <0.001 Cavalcante et al. J Am Coll Cardiol 2016;68:
15 Temporal Trends in Revascularization Strategy and Outcomes in Left Main Coronary Artery Stenosis Data From the Asan Medical Center-Left Main Revascularization Registry SJ Park et al. Circ Cardiovasc Interv. 2015;8:e
16 Left Main Stenosis The new evidence in 2016 NOBLE & EXCEL trials
17 NOBLE study PCI (Biomatrix, Biolimus) vs CABG 1201 patients Randomisation: 1 to 1 ratio LM and no more than 3 additional non complex PCI lesions Primary end point: Composite of all-cause mortality, non procedural MI, stroke, repeat revasc. (MACCE) at 5 years
18 PCI versus CABG in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial Primary end point: MACCE at 5 years PCI: 29%, CABG: 19%, p= Mäkikallio et al. Lancet 2016
19 PCI versus CABG in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial Mortality Myocardial infarction 12% vs 9%, p=0.77 7% vs 2%, p=0.004 Mäkikallio et al. Lancet 2016
20 PCI versus CABG in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial Repeat revascularisation Stroke 16% vs 10%, p= % vs 2%, p=0.073 Mäkikallio et al. Lancet 2016
21 PCI versus CABG in treatment of unprotected left main stenosis (NOBLE): a prospective, randomised, open-label, non-inferiority trial Kaplan-Meier 5 year estimates of MACCE were 29% for PCI (121 events) and 19% for CABG (81 events), HR 1 48 (95% CI ), exceeding the limit for non-inferiority, and CABG was significantly better than PCI (p=0 0066). The findings of this study suggest that CABG might be better than PCI for treatment of left main stem coronary artery disease. Mäkikallio et al. Lancet 2016
22 EXCEL study PCI (Xience, Everolimus) vs CABG 1905 patients Randomisation: 1 to 1 ratio Syntax score < 33 Non inferiority trial Primary end point: Composite of mortality, MI, stroke at 3 years
23 Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease EXCEL Trial Primary end point: Death, MI, Stroke at 3 years Stone et al. N Engl J Med, Nov 2016
24 Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease EXCEL Trial Components of the Primary end point at 3 years Stone et al. N Engl J Med, Nov 2016
25 Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease EXCEL Trial In patients with left main coronary artery disease and low or intermediate SYNTAX scores by site assessment, PCI with everolimus-eluting stents was noninferior to CABG with respect to the rate of the composite end point of death, stroke, or myocardial infarction at 3 years. Stone et al. N Engl J Med, Nov 2016
26 Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease EXCEL Trial Death, Stroke, MI at 30 days PCI (%) CABG (%) p value Death, stroke, MI Death Stroke MI Stone et al. N Engl J Med, Nov 2016
27 Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease EXCEL Trial Revascularisation & MACCE PCI (%) CABG (%) p value Ischemia-driven revasc <0.001 TVR non TVR All revascularisation <0.001 MACCE Stone et al. N Engl J Med, Nov 2016
28 Comparison between EXCEL (at 3 yrs) and NOBLE (at 5 years)
29 Why different results between NOBLE and EXCEL? EXCEL study NOBLE study Xience stent Biomatrix Stent 3 years FU 5 years FU PEP: All MI PEP: Only non procedural MI PEP without repeat revasc. PEP with repeat revasc. Positive Study Non Inferiority of PCI Negative study No Non inferiority of PCI Stone et al, NEJM 2016 Mäkikallio et al, Lancet 2016
30
31 Revascularisation for Left Main Lesion Basics for decision-making Knowledge Data from RCT s, registries, meta-analysis Guidelines Experience Results from local heart team Clinical Judgment Evolution of Technology & Techniques Global appraisal of the Patient
32 Basics for decision-making Global appraisal of the patient (1) Clinical characteristics: Age, gender, cognitive status Way of life, socio-cultural considerations Functional class Diabetes & other risk factors of CAD Previous cardio-vascular intervention Valvular disease, heart failure, COPD, Renal failure Peripheral artery disease, carotid artery lesions Other comorbidities No contra-indication for long term DAPT Euroscore
33 Basics for decision-making Global appraisal of the patient (2) Angiographic characteristics: LVEF LM lesion: distal /non distal calcification, bifurcation angle, diseased LCx ostium trifurcation MVD, number of lesions, diffuse disease Complexity of additional lesions: length, calcifications, bifurcations, Syntax score CTO (RCA occlusion), Complete or incomplete revascularisation. Number of stents needed, overlapping, complex bifurcations
34 Farooq et al. Lancet 2013; 381: SYNTAX score II
35 SYNTAX score II Prediction of the 4-year mortality Farooq et al. Lancet 2013; 381:
36 Revascularisation for Left Main Lesion Basics for decision-making Knowledge Data from RCT s, registries, meta-analysis Guidelines Experience Results from local heart team Clinical Judgment Evolution of Technology & Techniques Global appraisal of the Patient
37 Basics for decision-making Local experience of the heart team Evaluation of local practice: CABG & PCI Morbi/mortality meetings Share experience in technique & results Collegial consensus in patient care
38 Revascularisation for Left Main Lesion Basics for decision-making Knowledge Data from RCT s, registries, meta-analysis Guidelines Experience Results from local heart team Clinical Judgment Evolution of Technology & Techniques Global appraisal of the Patient
39 Basics for decision-making Evolution of the technology & techniques: Surgery: Arterial revasc. Midcab PCI: DES: new generation (bioadegradable polymer, polymer free) New antiplatelet agents (prasugrel, ticagrelor) Longer DAPT duration Hybrid procedures
40 Key Features of Contemporary DES Byrne RA et al. Lancet 2017; 390:
41 Target-lesion revascularization (%) Definite stent thrombosis (%) All-cause death (%) # Myocardial Infarction (%) Safety and efficacy of new generation DES 10 Death MI BMS Early DES New DES TLR BMS Early DES New DES BMS Early DES New DES Definite ST BMS Early DES New DES ESC-EAPCI Stent Task Force - Eur Heart J 2015
42 How do we evaluate the LM diameter? Visual estimation & QCA are not available Ø=3.5mm D d1 Ø= 4.5 5mm d2 Ø=3.5mm 1. IVUS 2. Murray s law, fractal law: D = 0.67 x (d1+d2)
43 Left Main Stenting 4.0x8mm DES Final result after post dilatation using a 4.5 mm balloon at 22 atm.
44 Ostial Left Main Lesion AP RAO view LAO-cranio view
45 Ostial Left Main Lesion Direct Stenting Stent deployment Balloon post dilatation
46 Ostial Left Main Lesion Final result
47 AP caudal view Mid-shaft Left Main Lesion
48 Distal Left Main PCI 1 stent technique: Provisional stenting 2-stent technique: TAP Culotte Minicrush, DK Crush V stenting
49 Distal Left Main PCI Strategy of LM stenting: 1 stent vs 2 stents Provisional T stenting: no lesion at SB ostium short < 5mm lesion at SB ostium small SB
50 Distal Left Main PCI Strategy of LM stenting: 1 stent vs 2 stents 2-stent strategy: poor result after provisional stenting long lesion beyond SB ostium complex stenosis at SB ostium diffuse and calcified atheroma
51 2-stent strategy: Distal Left Main PCI Bif. angle > 60 : T or TAP < 60 : Culotte, Minicrush, TAP Same size Culotte, TAP MB & SB sizes Different size Minicrush, TAP
52 Distal Left Main PCI 2-stent strategy One technique must be perfectly known The TAP technique
53 TAP technique
54 TAP technique
55 TAP technique
56 TAP technique
57 TAP technique
58 TAP technique
59 TAP technique
60 How to assess & optimize stent deployment 1. Pre dilatation: balloon,cutting, rotablator 2. Post dilatation: adequate size balloons with high pressure 3. KB after 2-stent implantation 4. Final POT 5. Evaluation of the result: QCA, Stent Boost/Vizz IVUS OCT
61 IVUS for LM ostium evaluation
62
63
64 LM lesions : PCI or CABG? Conclusion Patient selection is key Global appraisal of the patient (clinical & angiographic characteristics) Good results of PCI in selected patients Medical-surgical consultation Ethics of information
65 De Maria GL, et al. Heart 2018;104:
66 The future
67
Left Main Disease: what is left to surgery? Prof. Jacques Monségu CardioVascular Institute Grenoble, France
Left Main Disease: what is left to surgery? Prof. Jacques Monségu CardioVascular Institute Grenoble, France Background on LM stenosis 5% of patients undergoing angiography Of the myocardium 80% Bifurcation
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
Lésions du tronc commun: Reste t il une place pour la chirugie? Pierre Deharo, CHU TIMONE, Marseille
Lésions du tronc commun: Reste t il une place pour la chirugie? Pierre Deharo, CHU TIMONE, Marseille Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an
Left Main Intervention: Where are we in 2015?
Left Main Intervention: Where are we in 2015? David A. Cox, MD FSCAI Director, Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown, PA Fall Fellows Course Laa
Left Main PCI vs. CABG: Real World
Management of Patients with Stable CAD Left Main PCI vs. CABG: Real World Marco Roffi, MD, FESC University Hospital Geneva, Switzerland SYNTAX-LMT The SYNTAX trial included a pre-specified subgroup of
Unprotected LM intervention
Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline
Important LM bifurcation studies update
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Important LM bifurcation studies update I Sheiban E-mail: isheiban@yahoo.com Unprotected LM Percutaneous Revascularization What is important
Left Main Intervention: Will it become standard of care?
Left Main Intervention: Will it become standard of care? David Cox, MD FSCAI, FACC Director, Interventional Cardiology Research Associate Director, Cardiac Cath Lab Lehigh Valley Health Network Allentown,
LM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
Left Main PCI. Integrated Use of IVUS and FFR. Seung-Jung Park, MD, PhD
Left Main PCI Integrated Use of IVUS and FFR Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea Efficacy of Left
Assessing Myocardium at Risk: Applying SYNTAX
Assessing Myocardium at Risk: Applying SYNTAX Farouc Jaffer MD PhD FSCAI FACC FAHA Associate Professor of Medicine, Harvard Medical School Director, CAD Program and Chronic Total Occlusion PCI Program
Integrated Use of IVUS and FFR for LM Stenting
Integrated Use of IVUS and FFR for LM Stenting Gary S. Mintz, MD Cardiovascular Research Foundation Four studies have highlighted the inaccuracy of angiography in the assessment of LMCA disease Fisher
Percutaneous Intervention of Unprotected Left Main Disease
Percutaneous Intervention of Unprotected Left Main Disease Technical feasibility and Clinical outcomes Seung-Jung Park, MD, PhD, FACC Professor of Internal Medicine Asan Medical Center, Seoul, Korea Unprotected
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
Non-LM bifurcation studies of importance in 2011
7th European Bifurcation Club 14-15 October 2011 LISBON Goran Stankovic MD, PhD Non-LM bifurcation studies of importance in 2011 October 15 th : 08:00 08:10 DKCRUSH-II: A Prospective Randomized Trial of
Unprotected Left Main Stenting: Patient Selection and Recent Experience. Alaide Chieffo. S. Raffaele Hospital, Milan, Italy
Unprotected Left Main Stenting: Patient Selection and Recent Experience Alaide Chieffo S. Raffaele Hospital, Milan, Italy Class IIa (Level B) AHA/ACC 2005 Guidelines Left Main CAD The use of PCI for pts
Left Main and Bifurcation Summit I. Lessons from European LM Studies
Left Main and Bifurcation Summit I Apr 29 8.56-9.09 Lessons from European LM Studies Alaide Chieffo, MD S. Raffaele Hospital, Milan, Italy Nothing to disclose regarding this presentation Lesion Location
Upgrade of Recommendation
Challenges in LM PCI Decision-making process for stenting Young-Hak Kim, MD, PhD, Heart Institute, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea Upgrade of Recommendation for
Perspective of LM stenting with Current registry and Randomized Clinical Data
Asian Pacific TCT Perspective of LM stenting with Current registry and Randomized Clinical Data Patrick W. Serruys MD PhD Yoshinobu Onuma MD Seung-Jung Park MD, PhD 14:48-15:00, 2009 Symposium Arena, Level
Controversies in Cardiac Surgery
Controversies in Cardiac Surgery 3 years after SYNTAX : Percutaneous Coronary Intervention for Multivessel / Left main stem Coronary artery disease Pro ESC Congress 2010, 28 August 1 September Stockholm
PCI for LMCA lesions A Review of latest guidelines and relevant evidence
HCS Working Group Seminars Met Hotel, Thursday 14 th February 2013 PCI for LMCA lesions A Review of latest guidelines and relevant evidence Vassilis Spanos Interventional Cardiologist, As. Director 3 rd
FFR-guided Jailed Side Branch Intervention
FFR-guided Jailed Side Branch Intervention - Pressure wire in Bifurcation lesions - Bon-Kwon Koo, MD, PhD Seoul National University Hospital, Seoul, Korea Bifurcation Lesions Bifurcation Lesions Still
COMMENT DEFINIR UN PLURITRONCULAIRE. Didier Carrié CHU Toulouse Rangueil
COMMENT DEFINIR UN PLURITRONCULAIRE VISION ANGIOGRAHIQUE DU PLURITRONCULAIRE Didier Carrié CHU Toulouse Rangueil Congrès GRCI 03 Décembre 2010 Pôle Cardiovasculaire et Métabolique Avec quel œil je regarde
PCI vs. CABG From BARI to Syntax, Is The Game Over?
PCI vs. CABG From BARI to Syntax, Is The Game Over? Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea PCI vs CABG Multi-Vessel Disease
Unprotected left main coronary stenting with a second generation drug-eluting stent. One-year clinical follow-up of the LeMaX pilot study.
Unprotected left main coronary stenting with a second generation drug-eluting stent. One-year clinical follow-up of the LeMaX pilot study. N. Boudou, N. Salvatella, N. Dumonteil, M.C. Morice, O. Darremont,
ΑΝΤΙΓΝΩΜΙΕΣ ΣΤΗΝ ΕΠΕΜΒΑΤΙΚΗ ΚΑΡΔΙΟΛΟΓΙΑ:Νόσος στελέχους Αγγειοπλαστική
ΑΝΤΙΓΝΩΜΙΕΣ ΣΤΗΝ ΕΠΕΜΒΑΤΙΚΗ ΚΑΡΔΙΟΛΟΓΙΑ:Νόσος στελέχους Αγγειοπλαστική X. ΓΡΑΪΔΗΣ Επεμβατικός καρδιολόγος, FSCAI Kλινική Euromedica-Κυανούς Σταυρός, Θεσσαλονίκη The Fear factor The two words LEFT MAIN
The SYNTAX-LE MANS Study
The SYNTAX-LE MANS Study Synergy Between PCI with TAXUS Express and Cardiac Surgery: Late (15-month) Left Main Angiographic Substudy A. Pieter Kappetein, MD, PhD Erasmus MC, Rotterdam, NL SYNTAX-LE MANS
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki Hong, MD. PhD on behalf of the IVUS-XPL trial investigators
What do the guidelines say?
Percutaneous coronary intervention in 3-vessel disease and main stem What do the guidelines say? Nothing to disclose Dariusz Dudek Institute of Cardiology, Jagiellonian University Krakow, Poland The European
PROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
Rationale for Percutaneous Revascularization ESC 2011
Rationale for Percutaneous Revascularization Marie Claude Morice, Massy FR MD, FESC, FACC ESC 2011 Paris Villepinte - 27-31 August, 2011 Massy, France Potential conflicts of interest I have the following
Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD
Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD Onassis Cardiac Surgery Center, Athens, Greece Critical issues in LM PCI Anatomic variability Techniques Variability
Count Down to COMBAT
Count Down to COMBAT Randomized COMparison of Bypass Surgery versus AngioplasTy using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease Roxana Mehran, MD Associate Professor of
Implications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011
Implications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011 Prof. Dr. Volkmar Falk Klinik für Herz- und Gefäßchirurgie, Universitätsspital Zürich, Schweiz In 2004 headlines were
Chapter 29 Left Main Intervention in the Light of EXCEL and NOBLE Trials
Chapter 29 Left Main Intervention in the Light of EXCEL and NOBLE Trials DEBDATTA BHATTACHARYYA AYAN KAR The incidence of angiographically significant left main stenosis described in various studies has
New Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
Mid-term results from real-world REPARA registry. Felipe Hernandez, on behalf of the REPARA investigators
Mid-term results from real-world REPARA registry Felipe Hernandez, on behalf of the REPARA investigators Potential conflicts of interest Speaker's name: Felipe Hernandez I have the following potential
Most Patients with Elective Left Main Disease. Farrel Hellig
Most Patients with Elective Left Main Disease Should be Treated with PCI! Farrel Hellig Sunnnghill and Sunward Park Hospitals Johannesburg South Africa Everything that can be invented has been invented
I have nothing to disclose.
I have nothing to disclose. ESC congress of cardiology, 25-29th August 2012, Munich, Germany Minsk-Village 6, August 26 th, 2:22 PM Session: The grey zone of coronary interventions: The real bifurcation
Contemporary therapy of bifurcation lesions
Contemporary therapy of bifurcation lesions Dr Angela Hoye MB ChB PhD MRCP Interventional Cardiologist Kingston-upon-Hull, UK Hull The challenge of bifurcations Risk of peri-procedural infarction Relatively
PCI for Left Anterior Descending Artery Ostial Stenosis
PCI for Left Anterior Descending Artery Ostial Stenosis Why do you hesitate PCI for LAD ostial stenosis? LAD Ostial Lesion Limitations of PCI High elastic recoil Involvement of the distal left main coronary
Le# main treatment with Stentys stent. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy
Le# main treatment with Stentys stent Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement
Incidence and Treatment for LM In-Stent
Incidence and Treatment for LM In-Stent Restenosis Corrado Tamburino, MD, PhD Full Professor of Cardiology, Director of Postgraduate School of Cardiology Chief Cardiovascular Department, Director Cardiology
Side Branch Occlusion
Side Branch Occlusion Mechanism, Outcome, and How to avoid it From COBIS II Registry Hyeon-Cheol Gwon Cardiac&Vascular Center, Samsung Medical Center Sungkyunkwan University School of Medicine SB occlusion
Αγγειοπλαστική σε Nόσο Στελέχους: Που βρισκόμαστε. Βάιος Τζίφος Δ/ντής Τμήματος Επεμβατικής Καρδιολογίας Τομέας Καρδιάς Ερρίκος Ντυνάν Hospital Center
Αγγειοπλαστική σε Nόσο Στελέχους: Που βρισκόμαστε. Βάιος Τζίφος Δ/ντής Τμήματος Επεμβατικής Καρδιολογίας Τομέας Καρδιάς Ερρίκος Ντυνάν Hospital Center Δεν έχω οικονομική σχέση με φαρμακευτική εταιρία.
Final Clinical and Angiographic Results From a Nationwide Registry of FIREBIRD Sirolimus- Eluting Stent: Firebird In China (FIC) Registry (PI R. Gao)
The Microport FIREBIRD Polymer-based Sirolimus- Eluting Stent Clinical Trial Program Update: The FIC and FIREMAN Registries Junbo Ge, MD, FACC, FESC, FSCAI On behalf of Runlin Gao (FIC PI) and Haichang
Bifurcation stenting with BVS
Bifurcation stenting with BVS Breaking the limits or just breaking the struts? Maciej Lesiak Department of Cardiology University Hospital in Poznan, Poland Disclosure Speaker s name: Maciej Lesiak I have
LCX. President / Director of Cardiology / New Tokyo Hospital
LCX President / Director of Cardiology / New Tokyo Hospital Professor of Department of Advanced Cardiovascular Medicine: Kumamoto University Consultant / National Cardiovascular Center / Osaka Sunao Nakamura
Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) &
Are Asian Patients Different? - Updates Of Biomatrix Experience In Regional Settings: BEACON II (3 Yr F up) & Biomatrix TM Single Center Experience (Indonesia)(Final 5 Yr F up) T. Santoso University of
True Bifurcation LM Stenosis (Medina 1,1,1) With Very Extensive Calcification: CABG Or PCI?
True Bifurcation LM Stenosis (Medina,,) With Very Extensive Calcification: CABG Or PCI? T. Santoso University of Indonesia Medical School, Medistra Hospital, Jakarta, Indonesia PCI or CABG for Unprotected
Kurdistan Technique for the Treatment of Unprotected Trifurcation Left Main Stem Coronary Artery Lesion: Case Report
World Journal of Cardiovascular Diseases, 2014, 4, 483-491 Published Online August 2014 in SciRes. http://www.scirp.org/journal/wjcd http://dx.doi.org/10.4236/wjcd.2014.49058 Kurdistan Technique for the
Le# Main Interven-on: When Is It Appropriate. Femi Philip, MD Assistant Professor Of Medicine UC Davis
Le# Main Interven-on: When Is It Appropriate Femi Philip, MD Assistant Professor Of Medicine UC Davis Nil Disclosures Outline What is the LMCA? Should we revascularize severe LMCA disease? What revascularizacon
Drug Eluting Stents: Bifurcation and Left Main Approach
TCT Asia 2006 Drug Eluting Stents: Bifurcation and Left Main Approach Eberhard Grube MD FACC, FSCAI Heart Center,, Germany Stanford University, School of Medicine, CA, USA DES in High Risk Lesions TAXUS
PCI or CABG for unprotected left main coronary artery disease? new evidence justifies a change in perspective
Editorial PCI or CABG for unprotected left main coronary artery disease? new evidence justifies a change in perspective R. Andrew Archbold Barts Heart Centre, St. Bartholomew s Hospital, West Smithfield,
INSIDE INFORMATION YOU CAN T IGNORE
INSIDE INFORMATION YOU CAN T IGNORE Volcano, the Volcano logo and SyncVision are registered trademarks of Volcano Corporation. All other trademarks set-forth are properties of their respective owners.
LEFT MAIN PERCUTANEOUS CORONARY INTERVENTION. A/Prof Koh Tian Hai Medical Director National Heart Centre, Singapore
LEFT MAIN PERCUTANEOUS CORONARY INTERVENTION A/Prof Koh Tian Hai Medical Director National Heart Centre, Singapore Disclosures Advisory Panel, Asian Medical Board Medtronics, Abbott Vascular. Speaker-honoraria,
ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April Session: Left mains & bifurcation intervention
ANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC Seoul, Korea: 25-27 27 April 2007 Session: Left mains & bifurcation intervention An integrated approach to bifurcation lesions: lessons from years of randomized
ΣΥΜΠΛΟΚΕΣ ΑΓΓΕΙΟΠΛΑΣΤΙΚΕΣ ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΔΙΧΑΣΜΩΝ
ΣΥΜΠΛΟΚΕΣ ΑΓΓΕΙΟΠΛΑΣΤΙΚΕΣ ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΔΙΧΑΣΜΩΝ DR ΝΙΚΟΛΑΟΣ ΚΑΥΚΑΣ MD, FESC Διευθυντής, Υπεύθυνος Αιμοδ/κού Εργαστηρίου Καρδιολογική Κλινική Γεν. Νοσοκομείο ΚΑΤ-ΕΚΑ PCI in Coronary Bifurcations Bifurcations
OCTOBER. OCT Optimised Bifurcation Event Reduction. A Nordic Baltic British clinical outcome trial
OCT Optimised Bifurcation Event Reduction A Nordic Baltic British clinical outcome trial NIELS RAMSING HOLM, Skejby Denmark Study start: OCTOBER 2016 OCTOBER LMCA or non-lmca bifurcations with SB 2.5mm
SKG Congress, 2015 EVOLVE II. Stephan Windecker
SKG Congress, 2015 EVOLVE II Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland BIODEGRADABLE POLYMER DES Stefanini,
Ultimaster clinical results in left main and bifurcations
Left main and complex bifurcation stenting clinical results in left main and bifurcations GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of Cardiovascular and Pulmonary Sciences
Mise à Jour sur le traitement du Pluritronculaire Philippe Généreux, MD
Mise à Jour sur le traitement du Pluritronculaire Philippe Généreux, MD Columbia University Medical Center and The Cardiovascular Research Foundation, New York, USA Hôpital du Sacré-Coeur de Montréal,
The MAIN-COMPARE Study
Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:
FFR and intravascular imaging, which of which?
FFR and intravascular imaging, which of which? Ayman Khairy MD, PhD, FESC Associate professor of Cardiovascular Medicine Vice Director of Assiut University Hospitals Assiut, Egypt Diagnostic assessment
NOBLE and EXCEL: The debate for excellence in dealing with left main stenosis
O P E N A C C E S S 1 Aswan Heart Centre, Aswan, Egypt 2 Sultan Qaboos University Hospital, Muscat, Sultanate of Oman 3 Cairo University, Cairo, Egypt *Email: hatem.hosny@aswanheartcentre.com Lessons from
DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.
DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. In-stent restenosis (ISR) Remains important issue even in the
STENTYS for Le, Main Sten2ng. Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy
STENTYS for Le, Main Sten2ng Carlo Briguori, MD, PhD Clinica Mediterranea Naples, Italy Disclosure Statement of Financial Interest I, Carlo Briguori DO NOT have a financial interest/ arrangement or affilia2on
Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease
Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Prof. Ran Kornowski, MD, FESC, FACC Director - Division of Interventional Cardiology Rabin Medical Center and Tel Aviv University,
ΑΝΤΙΜΕΤΩΠΙΣΗ ΑΣΘΕΝΩΝ ΜΕ ΝΟΣΟ ΣΤΕΛΕΦΟΥΣ
ΑΝΤΙΜΕΤΩΠΙΣΗ ΑΣΘΕΝΩΝ ΜΕ ΝΟΣΟ ΣΤΕΛΕΦΟΥΣ Δ. ΤΣΙΚΑΔΕΡΗΣ MD,FESC ΘΕΣΣΑΛΟΝΙΚΗ 2012 Although LM patients population treated with stenting is usually reported as a single, homogeneous subgroup, LM disease encompasses
high SYNTAX Score? I Sheiban Division of Cardiology Interventional Card. University of Turin Turin / Italy
What to do with patients with high SYNTAX Score? I Sheiban Division of Cardiology Interventional Card. University of Turin San Giovanni Battista Hospital Turin / Italy Who are the patients with high SYNTAX
Intracoronary Imaging For Complex PCI A Pichard, L Satler, Ron Waksman, I Ben-Dor, W Suddath, N Bernardo, D Harrington.
Intracoronary Imaging For Complex PCI A Pichard, L Satler, Ron Waksman, I Ben-Dor, W Suddath, N Bernardo, D Harrington. Medstar Washington Hospital Center Washington, DC Conflict of Interest None for this
Patient. Clinical data Indications: Operation date. Comorbidities: Patient code Birth date: / /
Patient Patient code Birth date: / / Sex: Male Height (cm): Female Weight (kg): Risk Factors: Family history of coronary disease: Hypertension Dyslipidemia Peripheral disease Diabetes Comorbidities: No
Michael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX
Michael Mack, M.D. Baylor Healthcare System Heart Hospital Baylor Plano Dallas, TX Boston Scientific, Inc.- Syntax Trial Steering Committee Member- travel expenses paid by trial sponsor Maquet, Inc.- unpaid
The Tryton Side Branch System in Distal Left Main PCI
The Tryton Side Branch System in Distal Left Main PCI Yaron Almagor, MD Director, Interventional Cardiology Shaare Zedek Medical Center Jerusalem, Israel TCTAP Seoul April 2013 Speaker s name: YARON ALMAGOR
Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome
Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome Chris C. Cook, MD Associate Professor of Surgery Director, CT Residency Program, WVU ACOI 10/17/18 No Disclosures
CARDIOLOGY SYMPOSIUM 2015 CAROLINA CARDIOLOGY CONSULTANTS OF GHS
CARDIOLOGY SYMPOSIUM 2015 CAROLINA CARDIOLOGY CONSULTANTS OF GHS STENT, OPERATE, OR MEDICATE? DIFFERING PERSPECTIVES ON CORONARY REVASCULARIZATION JIM BAUCUM, MD FACC SCOTT JOHNSON, MD JANUARY 24, 2015
Perioperative Management After Coronary Stenting: Risk Assessment Before Surgery. Christian Seiler No conflict of interest to declare.
Perioperative Management After Coronary Stenting: Risk Assessment Before Surgery Christian Seiler No conflict of interest to declare PCI Long-Term Outcome Perioperative Management After Coronary Stenting:
Final Kissing Ballooning Returns? The analysis of COBIS II registry
Final Kissing Ballooning Returns? The analysis of COBIS II registry Hyeon- Cheol Gwon Heart Vascular & Stroke Ins?tute, Samsung Medical Center Sungkyunkwan University School of Medicine Final Kissing Ballooning
Stent Thrombosis in Bifurcation Stenting
Summit TCT Asia Pacific 2009 Stent Thrombosis in Bifurcation Stenting Associate Professor Tan Huay Cheem MBBS, M Med(Int Med), MRCP, FRCP(UK), FAMS, FACC, FSCAI Director, National University Heart Centre,
Coronary interventions
Controversial issues in the management of ischemic heart failure Coronary interventions Maciej Lesiak Department of Cardiology, University Hospital in Poznan none DECLARATION OF CONFLICT OF INTEREST CHF
Long-term outcomes of PCI vs. CABG for ostial/midshaft lesions in unprotected left main coronary artery
Journal of Geriatric Cardiology (2017) 14: 254 260 2017 JGC All rights reserved; www.jgc301.com Research Article Open Access Long-term outcomes of PCI vs. CABG for ostial/midshaft lesions in unprotected
A Paclitaxel-Eluting Balloon for Bifurcation Lesions : Early Clinical Observations
Innovative Devices : Non Stent Technologies : Drug Eluting Balloons A Paclitaxel-Eluting Balloon for Bifurcation Lesions : Early Clinical Observations Pieter R. Stella, MD Director CardioVascular Research
ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΣΤΟ ΔΙΑΒΗΤΙΚΟ ΑΣΘΕΝΗ
ΑΓΓΕΙΟΠΛΑΣΤΙΚΗ ΣΤΟ ΔΙΑΒΗΤΙΚΟ ΑΣΘΕΝΗ Νίκος Μεζίλης MD, FESC Κλινική Άγιος Λουκάς Why diabetes is associated with restenosis endothelial dysfunction metabolic alterations accelerated platelet deposition
What s New in Antiplatelet Therapy and DES in 2016
What s New in Antiplatelet Therapy and DES in 2016 Peter Pollak MD Director of Structural Heart Disease & Intervention Mayo Clinic Florida 2016 slide-1 Disclosures Financial None Off-label - None 2016
Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary Intervention
Original Article Print ISSN 1738-5520 On-line ISSN 1738-5555 Korean Circulation Journal Impact of Chronic Kidney Disease on Long-Term Outcome in Coronary Bypass Candidates Treated with Percutaneous Coronary
PCI for Long Coronary Lesion
PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2
IVUS vs FFR Debate: IVUS-Guided PCI
IVUS vs FFR Debate: IVUS-Guided PCI Gary S. Mintz, MD Cardiovascular Research Foundation New York, NY Disclosure Statement of Financial Interest Within the past 12 months, I have had a financial interest/arrangement
ΣΥΜΠΛΟΚΕΣ ΔΙΑΔΕΡΜΙΚΕΣ ΕΠΕΜΒΑΣΕΙΣ (στέλεχος, διχασµός, µακρές πολλαπλές βλάβες)
ΣΥΜΠΛΟΚΕΣ ΔΙΑΔΕΡΜΙΚΕΣ ΕΠΕΜΒΑΣΕΙΣ (στέλεχος, διχασµός, µακρές πολλαπλές βλάβες) ΠΕΤΡΟΣ Σ. ΔΑΡΔΑΣ, MD, FESC 16o Βορειοελλαδικό Καρδιολογικό Συνέδριο ΘΕΣΣΑΛΟΝΙΚΗ 2017 Left Main Disease 5-year Outcomes (N=705)
Benefit of Performing PCI Based on FFR
Benefit of Performing PCI Based on FFR William F. Fearon, MD Associate Professor Director, Interventional Cardiology Stanford University Medical Center Benefit of FFR-Guided PCI FFR-Guided PCI vs. Angiography-Guided
Coronary Revascularization for Patients with Severe Coronary Artery Disease: An Overview of Current Evidence and Treatment Strategies
Review J Jpn Coron Assoc 2015; 21: 267-271 Coronary Revascularization for Patients with Severe Coronary Artery Disease: An Overview of Current Evidence and Treatment Strategies Hiroki Shiomi, Takeshi Kimura
Conflict of interest :None. Meta-analysis. Zhangwei Chen, MD
Meta-analysis Addition of Cilostazol to Conventional Dual Antiplatelet Therapy Reduces the Risk of Cardiac Events and Restenosis after Drug-Eluting Stent Implantation Zhangwei Chen, MD Department of Cardiology,
Protection of side branch is essential in treating bifurcation lesions: overview
Angioplasty Summit TCT Asia Pacific Seoul, April 26-28, 2006 Protection of side branch is essential in treating bifurcation lesions: overview Alfredo R Galassi, MD, FACC, FSCAI, FESC Head of the Catetherization
Abbott Vascular. PROTOCOL EXCEL Clinical Trial
Abbott Vascular PROTOCOL Clinical Trial Evaluation of XIENCE PRIME or XIENCE V versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization PCI (1 st gen DES) vs. CABG for Left
in an Unyielding Patient Dr Jason See, Dr Goh Yew Seong, Dr Rohit Khurana Changi General Hospital Singapore
Unrelenting Left Main Disease in an Unyielding Patient Dr Jason See, Dr Goh Yew Seong, Dr Rohit Khurana Changi General Hospital Singapore Clinical History 72 years old Chinese lady Background and CV Risk
PCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
Nobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy
Nobori Clinical Studies Up-dates Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy Drug Eluting Stents High benefit in preventing restenosis and improving quality of life
Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!
Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Young-Hak Kim, MD, PhD Heart Institute, University of Ulsan College of Medicine Asan Medical Center,